Synthetic spider silk proteins sales will expand through 2036, with clinical-grade proteins holding 51.7% of the claim segment in 2026. The market was valued at USD 0.95 billion in 2025 and is expected to be worth USD 4.17 billion by 2036, creating an incremental opportunity of USD 3.08 billion.